In recognition of these limitations, we devised an innovative immunohistochemical scoring system for CDX2 expression assessment (CDX2 expression categories 1, 2, and 3), as well as a novel classification of the tumor differentiation patterns (categories 1, 2, 3, and 4), shedding light on the complex molecular heterogeneity of colon cancer. This evidence concerns the gene CDX2 and colonic neoplasm.